NDAINTRAVENOUSPOWDERPriority Review
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEZABY is an intravenous powder formulation of phenobarbital sodium, a long-acting barbiturate approved in November 2022. It is indicated for acute seizure management and sedation in critical care settings. The drug works by enhancing GABAergic inhibition in the central nervous system, depressing neuronal activity.
Peak15.4 years to LOE
Limited publicly available spending data suggests this is a niche hospital-based product with modest commercial infrastructure compared to primary care or high-volume specialty drugs.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SEZABY offers limited career visibility based on zero linked job postings, indicating a small or highly specialized team within PharmaIN's portfolio. This is a niche hospital product with modest commercial scale compared to primary care launches.
Hospital Account ManagerPharmacy Sales Representative
Worked on SEZABY at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.